A Study to Investigate Blood-derived Circulating Tumor DNA, Circulating Tumor RNA, and Circulating Tumor miRNA in Pancreatic Cancer Patients


About this study

The purpose of this study is to establish a cohort of 200 patients receiving definitive radiotherapy at Mayo Clinic Florida for locally advanced pancreatic cancer (T3-4NxM0; TxN+M0), and establish a biobank of 10 ml of plasma (frozen at –80o C) for each patient at baseline (prior to starting radiation treatment), week 2 of radiation treatment and 4-8 weeks following radiation treatment.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adult patients (> 18 years of age).
  • Receiving definitive chemoradiotherapy at Mayo Clinic Florida for locally advanced or borderline resectable pancreatic cancer (T3-4NxM0; TxN+M0).  

Exclusion Criteria: 

  • Adult patients not willing/able to provide informed consent.
  • Patients < 18 years of age.
  • Patients with HIV infection or Hepatitis infection.

Eligibility last updated 10/22/21. Questions regarding updates should be directed to the study team contact.


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Sunil Krishnan, M.B.B.S., M.D.

Open for enrollment

Contact information:

Jacquelyn Gardner

(904) 953-3777


More information


Publications are currently not available

Mayo Clinic Footer